Jenny Down

839 total citations
15 papers, 320 citations indexed

About

Jenny Down is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jenny Down has authored 15 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Jenny Down's work include Bone health and treatments (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Prostate Cancer Treatment and Research (4 papers). Jenny Down is often cited by papers focused on Bone health and treatments (6 papers), Multiple Myeloma Research and Treatments (4 papers) and Prostate Cancer Treatment and Research (4 papers). Jenny Down collaborates with scholars based in United Kingdom, Switzerland and Australia. Jenny Down's co-authors include Peter I. Croucher, Colby L. Eaton, Freddie C. Hamdy, Simon S. Cross, Michael J. Rogers, Andrew Parker, Nicholas Pocock, Alexander Swarbrick, Akira Nguyen and Katherine N. Weilbaecher and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Jenny Down

14 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jenny Down United Kingdom	10	133	126	73	58	38	15	320
Eric C. Yang Canada	8	182 1.4×	132 1.0×	92 1.3×	51 0.9×	34 0.9×	14	411
Ilsa Coleman United States	5	203 1.5×	116 0.9×	99 1.4×	114 2.0×	70 1.8×	7	433
Devadarssen Murdamoothoo France	8	111 0.8×	120 1.0×	101 1.4×	33 0.6×	65 1.7×	10	330
Tristan Rupp France	9	142 1.1×	103 0.8×	73 1.0×	42 0.7×	86 2.3×	12	343
Kwabena Badu-Nkansah United States	6	201 1.5×	70 0.6×	38 0.5×	29 0.5×	54 1.4×	7	336
Paige M. Glumac United States	3	164 1.2×	196 1.6×	41 0.6×	47 0.8×	84 2.2×	4	317
Natalie L. Lister Australia	9	137 1.0×	148 1.2×	111 1.5×	81 1.4×	45 1.2×	12	364
Maria Magdalena Koczorowska Germany	7	150 1.1×	148 1.2×	36 0.5×	24 0.4×	101 2.7×	11	324
Otto Zach Austria	10	176 1.3×	216 1.7×	36 0.5×	67 1.2×	176 4.6×	28	447
Sven S. Liebler Germany	6	296 2.2×	105 0.8×	75 1.0×	25 0.4×	95 2.5×	8	520

Countries citing papers authored by Jenny Down

Since Specialization

Citations

This map shows the geographic impact of Jenny Down's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jenny Down with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jenny Down more than expected).

Fields of papers citing papers by Jenny Down

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jenny Down. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jenny Down. The network helps show where Jenny Down may publish in the future.

Co-authorship network of co-authors of Jenny Down

This figure shows the co-authorship network connecting the top 25 collaborators of Jenny Down. A scholar is included among the top collaborators of Jenny Down based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jenny Down. Jenny Down is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Tazzyman, Simon, Yidan Sun, Darren Lath, et al.. (2025). An oncolytic adenovirus targeting SLAMF7 demonstrates anti-myeloma efficacy. Leukemia. 39(6). 1449–1463.

Blount, Daniel G., Naeem Khan, Laura Moyce, et al.. (2024). Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia. Molecular Cancer Therapeutics. 24(1). 93–104. 2 indexed citations

Crabb, Simon J., David A. Cairns, Michelle Collinson, et al.. (2024). Use of gene expression patterns to identify unique molecular subtypes in muscle invasive bladder cancer: GUSTO.. Journal of Clinical Oncology. 42(16_suppl). TPS4621–TPS4621. 1 indexed citations

Griffin, Jon, Jenny Down, Paul R. Heath, et al.. (2024). Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. The Journal of Pathology Clinical Research. 10(2). e12363–e12363. 10 indexed citations

Migneco, G, Gina B. Scott, Jenny Down, et al.. (2021). Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer. 9(3). e001803–e001803. 14 indexed citations

Lath, Darren, Clive Buckle, Holly Evans, et al.. (2018). ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo. PLoS ONE. 13(6). e0199517–e0199517. 10 indexed citations

Paton‐Hough, Julia, Simon Tazzyman, Holly Evans, et al.. (2018). Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. Journal of Bone and Mineral Research. 34(5). 783–796. 16 indexed citations

Tazzyman, Simon, Darren Lath, Jenny Down, et al.. (2018). Myeloma-Specific Oncolytic Adenovirus Induces Significant Tumour Oncolysis In Vitro and In Vivo and Prevents Cell Line Regrowth. Blood. 132(Supplement 1). 3213–3213. 2 indexed citations

Chai, Ryan C., Michelle M. McDonald, Rachael Terry, et al.. (2017). Melphalan modifies the bone microenvironment by enhancing osteoclast formation. Oncotarget. 8(40). 68047–68058. 9 indexed citations

10.

Bassett, J. H. Duncan, Anne H. van der Spek, John G. Logan, et al.. (2015). Thyrostimulin Regulates Osteoblastic Bone Formation During Early Skeletal Development. Endocrinology. 156(9). 3098–3113. 32 indexed citations

11.

Junankar, Simon, Gemma Shay, Julie Jurczyluk, et al.. (2014). Real-Time Intravital Imaging Establishes Tumor-Associated Macrophages as the Extraskeletal Target of Bisphosphonate Action in Cancer. Cancer Discovery. 5(1). 35–42. 119 indexed citations

12.

Reeves, Kimberley J., Marco Cecchini, Gabri van der Pluijm, et al.. (2014). Prostate cancer cells home to bone using a novel in vivo model: Modulation by the integrin antagonist GLPG0187. International Journal of Cancer. 136(7). 1731–1740. 11 indexed citations

13.

Mathew, Grinu, Andrew J. Mitchell, Jenny Down, et al.. (2013). Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer. Scientific Reports. 3(1). 2792–2792. 27 indexed citations

14.

Rehman, Ishtiaq, Caroline A. Evans, Adam Glen, et al.. (2012). iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer. PLoS ONE. 7(2). e30885–e30885. 58 indexed citations

15.

Rehman, Ishtiaq, Caroline A. Evans, Adam Glen, et al.. (2012). Correction: iTRAQ Identification of Candidate Serum Biomarkers Associated with Metastatic Progression of Human Prostate Cancer. PLoS ONE. 7(5). 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact